Eledon Pharmaceuticals, Inc.
ELDNNext catalyst
No upcoming catalyst in our data
No upcoming FDA decision, filing or trial readout is on file for ELDN. That does not mean none is planned.
Get an email about ELDN's next catalysts
Track Eledon Pharmaceuticals (ELDN) and we email you when an FDA date moves, 7 days and 1 day before the decision when the exact day is known, and when it is announced. Free account, no card.
1 upcoming event in our data (earnings).See the timeline
2 upcoming, 0 past
ELDN Earnings Report
Date estimated from past reporting pattern, not yet confirmed by the company | EPS Est: $-0.20 | FQ end Sep/2026 | Call: tbd
AT-1501 Phase 2 Est. Readout
Estimated primary completion for AT-1501 trial (NCT05027906) in Prevention of Rejection in Kidney Transplant. Topline data typically follows completion by weeks to months.
New patient-reported outcomes data from the Phase 2 BESTOW trial showed sustained improvements in quality of life and symptom burden with tegoprubart compared to tacrolimus.
SourceMarket Overview
Stock performance and key metrics
AT-1501
Kidney Transplant Rejection
Islet transplantation with Tegoprubart (AT-1501) immunosupression-based therapy
Type 1 Diabetes Mellitus
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
AT-1501 | Phase 2 | Kidney Transplant Rejection | - | - |
Islet transplantation with Tegoprubart (AT-1501) immunosupression-based therapy | Phase 2 | Type 1 Diabetes Mellitus | - | - |
Frequently asked questions
What is in Eledon Pharmaceuticals, Inc.'s drug pipeline?→
CatalystAlert tracks 2 drug candidates in Eledon Pharmaceuticals, Inc.'s (ELDN) pipeline across Phase 2. Its lead program is AT-1501 (Phase 2). Each drug's phase, indication and upcoming catalysts are listed on this page.
When is Eledon Pharmaceuticals, Inc.'s next FDA catalyst?→
CatalystAlert tracks every upcoming catalyst for Eledon Pharmaceuticals, Inc. (ELDN) — PDUFA decision dates, Phase 1/2/3 trial readouts, FDA advisory committee meetings and NDA/BLA filings — each confidence-rated as confirmed, estimated or AI-detected.
How do I track ELDN biotech catalysts?→
Add ELDN to your CatalystAlert watchlist for alerts ahead of each catalyst, and follow Eledon Pharmaceuticals, Inc.'s live catalyst calendar, drug pipeline and clinical-trial timeline on this page — sourced from ClinicalTrials.gov, FDA and SEC filings.